阿托伐他汀治疗伴颈动脉粥样硬化的高血脂患者临床观察(3)
 |
| 第1页 |
参见附件(3128KB，3页)。
[7]Nssen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive compared with moderate lipid-lowering theraing therapy on progression of coronary atherosclerosis:a randomized controlled trial[J].JAMA,2004,291:1071.
[8]Cannon CP,Braunwald E,McCabe CH,et al.Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infartion 22 inverstigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Eng J Med,2004,350:1495.
[9]严宝霞.临床药学各论[M].北京:北京医科大学出版社,1999:81-86.
[10]王树岩,杨新春,杨中苏,等.辛伐他汀对急性心肌梗死合并心房颤动患者的疗效观察[J].中华心血管杂志,2008,33(1):88.
[11]李红元,韩迪,王乃东.阿托伐他汀对脑血栓患者血脂及颈动脉粥样硬化的影响[J].山东医药,2007(34):65-66.
[12]Saito S,Takayama T,Honye J,et al.Effect of lipid-lowering therapy on plaquevolume and composition in patient with coronary artery disease evaluated by three dimensional intravascular ultrasound[J].中国循环杂志,2002,11(17):143.
[13]Jones PH,Kafone KS,Iaurora I,et al.Comparative does efficacy study of atorvastatin versus simvastatin,pravastatin,lovastatin and fluvastatin in patiens with hypercholesterolemia(the CURBES study)[J].Am J Cardiol,1998,81(5):585.
[14]N aoumova RP,M araisAD,Mountney J,et al.Plasmamevalonic acid,an index of cholesterol synthesis in vivo,and responsiveness to HM G-COA reductase inhibitors in familial hypercholesterolaem[J].A therosclerosis,1996,119:203-213.
[15]北京阿托伐他汀临床试验协作组.阿托伐他汀治疗高脂血症的疗效和安全性[J].中华心血管病杂志,2001,29(3):132-135.
[16]Downs JR,Clearfield M,Whitney E,et al.Primary prevention of acute coronary events with lovastatin in men and women with average choresterol levels[J].JAMA,1998,279:1615-1622.
[17]Byerre LM,Lelorier J.Dostarins caves eancey Ametaanalysis of large randomized elinieal trailas[J].Aon J Med,2001,110(9):716-723.
[18]国家食品药品监督局药品评审中心,四川美达医药软件研究开发有限公司.药物临床信息参考[M].成都:四川科学技术出版社,2004:470-480.
(收稿日期：2010-12-27)
注：本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文
您现在查看是摘要介绍页，详见PDF附件(3128KB，3页)。